|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Global Hepatitis C Virus (HCV) Market– An Analysis
Price: $800.00 (€626.38) ($960.00 (€751.65) Including VAT at 20%)
|
| Publication Date: Aug-2011
Format: PDF Email
Pages: 47
Publisher: Koncept Analytics
Hepatitis C virus (HCV) is commonly spread through blood from a person who has been infected through use of shared needles or equipment used to inject drugs. HCV is a liver-infecting virus that causes acute (new and short-lived) and chronic (long-lasting) forms of hepatitis C.
The incidence rates of HCV vary noticeably, registering the highest rate in the North America. In the past few years, the cases of HCV have increased tremendously in the US, European, Asian and African regions. Comprising of two segments - diagnostic and treatment, the HCV market is driven by various factors like growing world population, obesity, increasing number of HCV incidences globally and rise in number of HCV positive drug addicts.
The global market for HCV drugs represents an area of potential opportunity in both developed and developing countries. Due to the effectiveness and advancements in technologies, large number of companies are focused on developing innovative HCV drugs. Further, the companies are forming alliances and agreements to develop effective treatments for HCV. In the long-term, the growth of global HCV drugs market is expected to come more from emerging markets like the Asia-Pacific, Middle East countries, African and Latin America countries as these regions are likely to register maximum number of HCV incidences in years to come due to increase in number of HCV positive drug addicts.
This report titled “Global Hepatitis C Virus (HCV) Market– An Analysis” analyzes the various types, stages and incidences of HCV in different geographies. In the report, the markets for diagnosis and treatment of hepatitis C virus, including overall HCV drugs market, have been analyzed. The report also discusses the various factors that will drive the HCV diagnosis and treatment market. Key HCV market trends and issues have also been discussed. The report also presents the competitive structure of the industry and profiles major players in the HCV drugs market including Roche, Merck Pharmaceutical and Vertex Pharmaceutical.
Further, we have predicted the future growth of the global HCV drugs market by combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings. We employed various significant variables that have an impact on this industry and created regression models with SPSS to determine the future direction of the industry.
Table of Contents/List of Tables/List of Figures |
|
|
R&D Trends: Hepatitis C
Price: $3,800.00 (€2,975.28) ($4,560.00 (€3,570.34) Including VAT at 20%)
|
| Publication Date: 14-Mar-2011
Please click here for more information or to purchase this report at our partner store
As new hepatitis C products advance into clinical development, the design of clinical studies and treatment regimens is becoming increasingly complex. This module reviews pipeline trends, clinical trial design and future treatment paradigms. |
|
|
Epidemiology: Hepatitis B in China - Hepatitis B will continue to remain a public health burden in China, despite a a projected decrease in prevalent cases
Price: $5,700.00 (€4,462.92) ($6,840.00 (€5,355.51) Including VAT at 20%)
|
| Publication Date: 12-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of hepatitis B definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year prevalent forecast and key patient segments across an emerging market. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epidemiology: Hepatitis C
Price: $5,700.00 (€4,462.92) ($6,840.00 (€5,355.51) Including VAT at 20%)
|
| Publication Date: 07-Feb-2011
Please click here for more information or to purchase this report at our partner store
Overview of hepatitis C and a review of epidemiology literature. This report provides in-depth analysis of patient populations, 10 year prevalent forecast, and key patient segments, including age, gender and genotype, across the seven major markets. |
|
|
R&D Trends: Hepatitis C
Price: $3,800.00 (€2,975.28) ($4,560.00 (€3,570.34) Including VAT at 20%)
|
| Publication Date: 14-Mar-2011
Please click here for more information or to purchase this report at our partner store
As new hepatitis C products advance into clinical development, the design of clinical studies and treatment regimens is becoming increasingly complex. This module reviews pipeline trends, clinical trial design and future treatment paradigms. |
|
|
Epidemiology: Hepatitis B in China
Price: $5,700.00 (€4,462.92) ($6,840.00 (€5,355.51) Including VAT at 20%)
|
| Publication Date: 12-Mar-2011
Please click here for more information or to purchase this report at our partner store
Overview of hepatitis B definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10 year prevalent forecast and key patient segments across an emerging market. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Innovations in Combating Infectious Diseases
Price: $3,835.00 (€3,002.69) ($4,602.00 (€3,603.22) Including VAT at 20%)
|
| Publication Date: 23-Jun-2010
Please click here for more information or to purchase this report at our partner store
Despite significant breakthroughs achieved during the last century in the development of antibiotic, antiviral, and antiparasitic drugs and vaccines, the eradication or even control of many infectious diseases has not been accomplished. |
|
|
Hepatitis B Market Forecast
Price: $15,200.00 (€11,901.13) ($18,240.00 (€14,281.35) Including VAT at 20%)
|
| Publication Date: 02-Aug-2010
Please click here for more information or to purchase this report at our partner store
This model contains a ten year commercial forecast of hepatitis B drug sales by country, class, molecule and brand across the US, Japan, France, Germany, Italy, Spain, UK and Turkey. |
|
|
Infectious Diseases Vaccine Market Overview
Price: $15,200.00 (€11,901.13) ($18,240.00 (€14,281.35) Including VAT at 20%)
|
| Publication Date: 25-Oct-2010
Please click here for more information or to purchase this report at our partner store
This report provides an overview of the vaccines industry with detailed profiles of the 5 major vaccine companies. It analyzes trends, sales, R&D and licensing strategies, portfolios and pipelines as well as other individual strengths & weaknesses. |
|
|
Stakeholder Opinions: Tropical Diseases - Dengue, Japanese encephalitis and West Nile virus – Increasing attention for neglected diseases
Price: $3,800.00 (€2,975.28) ($4,560.00 (€3,570.34) Including VAT at 20%)
|
| Publication Date: 14-Dec-2010
Please click here for more information or to purchase this report at our partner store
This report explores key issues in dengue, Japanese encephalitis and West Nile infection. It contains an analysis of epidemiological trends, assessment of marketed vaccines and discusses the pipeline for vaccines and virus-specific therapeutics. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Be alerted by email of new featured reports
Browse upcoming events or submit your own